EMBRACE reported 12-month suppression rates of 94% (IV N6LS+CAB LA), 82% (SC), and 88% (oral SOC), with no virologic failures and no new clinically significant AEs after month 6. Presentations focused ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results